
Several therapies are available for the treatment of superficial basal cell carcinoma (BCC), including excision, PDT, 5-fluorouracil and imiquimod; however, not all of them have the same safety and efficacy profile. A recent study proves that imiquimod is safe and effective for the treatment of superficial BCC and assures sustained clearance over at least five years.